Circadacare integrates circadian light technology with a real-time monitoring platform—Heleos, an easy-to-install light bulb—to support sleep, reduce falls, improve cognition and alleviate ‘sundowning’ in people with dementia. The company says its tech provides consistent home lighting and behavioural monitoring to detect deviations and enable longer independent living. Circadacare will use the new funding to drive product research, development, team growth and market expansion. Management highlights the potential to reduce reliance on healthcare providers and ease strain on social care resources. The business cites UK dementia prevalence and the high share living at home to underline market need and impact. Financially, the company announced a fresh funding package including grant awards alongside investor capital to accelerate commercial and product activity.

Total raised

$4M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2024